Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: Implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study

British Journal of Cancer

Volumn 111, Issue 12, 2014, Pages 2297-2307

  Kobel M ^a   Madore, J ^b,c   Ramus, S J ^d   Clarke, B A ^e   Pharoah, P D P ^f,g   Deen, S ^h   Bowtell, D D ^i,j   Odunsi, K ^k   Menon, U ^l   Morrison, C ^k   Lele, S ^k   Bshara, W ^k   Sucheston, L ^k   Beckmann, M W ^m   Hein, A ^m   Thiel, F C ^m   Hartmann, A ^m   Wachter, D L ^m   Anglesio, M S ^b   Hogdall E ^n,o   Jensen, A ⁿ   Hogdall C ^o   Kalli, K R ^p   Fridley, B L ^q   Keeney, G L ^p   Fogarty, Z C ^p   Vierkant, R A ^p   Liu, S ^r   Cho, S ^p   Nelson, G ^a   Ghatage, P ^a   Gentry Maharaj, A ^l   Gayther, S A ^d   Benjamin, E ^l   Widschwendter, M ^l   Intermaggio, M P ^d   Rosen, B ^s   Bernardini, M Q ^s   MacKay, H ^e   Oza, A ^s   Shaw, P ^s   Jimenez Linan, M ^t,u   Driver, K E ^g   Alsop, J ^g   MacK, M ^v   Koziak, J M ^w   Steed, H ^w   Ewanowich, C ^x   Defazio, A ^y   Chenevix Trench, G ⁱ   Fereday, S ^x   Gao, B ^y   Johnatty, S E ⁱ   George, J ⁱ   Galletta, L ⁱ   Goode, E L ^p   Kjaer S K ^n,o   Huntsman, D G ^b,z   Fasching, P A ^m,aa   Moysich, K B ^k   Brenton, J D ^u,ab,ac   Kelemen, L E ^ad   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h QUEEN S MEDICAL CENTRE   (United Kingdom)

ⁱ PETER MACCALLUM CANCER CENTRE   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k ROSWELL PARK CANCER INSTITUTE   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁿ DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^o UNIVERSITY OF COPENHAGEN   (Denmark)

^p MAYO CLINIC   (United States)

^q UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^r FOOTHILLS HOSPITAL   (Canada)

^s PRINCESS MARGARET HOSPITAL   (Canada)

^t ADDENBROOKE S HOSPITAL   (United Kingdom)

^u The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^v ALBERTA HEALTH SERVICES   (Canada)

^w ROYAL ALEXANDRA HOSPITAL   (Canada)

^x UNIVERSITY OF SYDNEY   (Australia)

^y QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^z BRITISH COLUMBIA CANCER AGENCY   (Canada)

^aa UNIVERSITY OF CALIFORNIA   (United States)

^ab UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ac Cambridge Experimental Cancer Medicine Centre   (United Kingdom)

^ad MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

folate receptor alpha; FRA; immunohistochemistry; ovarian cancer; prognosis; TCGA

Indexed keywords

FOLATE RECEPTOR 1; MESSENGER RNA; FOLR1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER GENETICS; CANCER GENOME ATLAS; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC DATABASE; HIGH GRADE SEROUS OVARIAN CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARIAN CLEAR CELL CARCINOMA; OVARIAN MUCINOUS CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TISSUE MICROARRAY; UPREGULATION; BIOSYNTHESIS; DISEASE FREE SURVIVAL; METABOLISM; NEOPLASM; OVARY TUMOR; SURVIVAL;

BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; FOLATE RECEPTOR 1; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84928651145     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.567     Document Type: Article

References (50)

1. Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG (2011) Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 121(2): 407-415.
2. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL (2013) Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 129(3): 452-458.
3. Balogun N, Gentry-Maharaj A, Wozniak EL, Lim A, Ryan A, Ramus SJ, Ford J, Burnell M, Widschwendter M, Gessler SF, Gayther SA, Jacobs IJ, Menon U (2011) Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol 64(5): 525-530.
4. Bromley AB, Altman AD, Chu P, Nation JG, Nelson GS, Ghatage P, Kalloger SE, Han G, Kobel M (2012) Architectural patterns of ovarian/pelvic high-grade serous carcinoma. Int J Gynecol Pathol 31(5): 397-404.
5. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5): 401-404.
6. Chen YL, Chang MC, Huang CY, Chiang YC, Lin HW, Chen CA, Hsieh CY, Cheng WF (2012) Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 6(3): 360-369.
7. Crane LM, Arts HJ, van Oosten M, Low PS, van der Zee AG, van Dam GM, Bart J (2012) The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr) 35(1): 9-18.
8. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y (2007) The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19(1): 3-9.
9. Despierre E, Lambrechts S, Leunen K, Berteloot P, Neven P, Amant F, O'Shannessy DJ, Somers EB, Vergote I (2013) Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol Oncol 130(1): 192-199.
10. Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L (2007) Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 7: 6.
11. Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E, Bock JE, Blaakaer J (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164(20): 2253-2259.
12. Goode EL, Chenevix-Trench G, Hartmann LC, Fridley BL, Kalli KR, Vierkant RA, Larson MC, White KL, Keeney GL, Oberg TN, Cunningham JM, Beesley J, Johnatty SE, Chen X, Goodman KE, Armasu SM, Rider DN, Sicotte H, Schmidt MM, Elliott EA, Hogdall E, Kjaer SK, Fasching PA, Ekici AB, Lambrechts D, Despierre E, Hogdall C, Lundvall L, Karlan BY, Gross J, Brown R, Chien J, Duggan DJ, Tsai YY, Phelan CM, Kelemen LE, Peethambaram PP, Schildkraut JM, Shridhar V, Sutphen R, Couch FJ, Sellers TA (2011) Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev 20(8): 1638-1648.
13. He W, Kularatne SA, Kalli KR, Prendergast FG, Amato RJ, Klee GG, Hartmann LC, Low PS (2008) Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer 123(8): 1968-1973.
14. Hein A, Thiel FC, Bayer CM, Fasching PA, Haberle L, Lux MP, Renner SP, Jud SM, Schrauder MG, Muller A, Wachter D, Strehl J, Hartmann A, Beckmann MW, Rauh C (2013) Hormone replacement therapy and prognosis in ovarian cancer patients. Eur J Cancer Prev 22(1): 52-58.
15. Hosmer DW, Lameshow SL (1999) Applied Survival Analysis: Regression Modeling of Time to Event Data. John Wiley & Sons Inc: New York, NY, USA.
16. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC (2008) Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108(3): 619-626.
17. Kamen BA, Smith AK (2012) Farletuzumab, an anti-folate receptor alpha antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemother Pharmacol 70(1): 113-120.
18. Kane MA, Elwood PC, Portillo RM, Antony AC, Najfeld V, Finley A, Waxman S, Kolhouse JF (1988) Influence on immunoreactive folatebinding proteins of extracellular folate concentration in cultured human cells. J Clin Invest 81(5): 1398-1406.
19. Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119(2): 243-250.
20. Kelemen LE, Kobel M, Chan A, Taghaddos S, Dinu I (2013) Differentially methylated loci distinguish ovarian carcinoma histological types: evaluation of a DNA methylation assay in FFPE tissue. Biomed Res Int 2013: 815894.
21. Kelemen LE, Sellers TA, Keeney GL, Lingle WL (2005) Multivitamin and alcohol intake and folate receptor alpha expression in ovarian cancer. Cancer Epidemiol Biomarkers Prev 14(9): 2168-2172.
22. Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR (2006) T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 24(26): 4254-4261.
23. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5(12): e232.
24. Kobel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GL, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich K, Edwards R, Modugno F, Bunker C, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, Gilks CB, Huntsman DG, Ramus SJ, Goode EL (2013) Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev 22(10): 1677-1686.
25. Kobel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD (2010a) Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol 116(1): 50-56.
26. Kobel M, Reuss A, Bois A, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB (2010b) The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 222(2): 191-198.
27. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, Larson SM, Old LJ (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16(21): 5288-5295.
28. Leamon CP, Reddy JA (2004) Folate-targeted chemotherapy. Adv Drug Deliv Rev 56(8): 1127-1141.
29. Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB (2012) Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology 23(2): 311-319.
30. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4): 387-391.
31. Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122(1): 170-176.
32. Miotti S, Bagnoli M, Tomassetti A, Colnaghi MI, Canevari S (2000) Interaction of folate receptor with signaling molecules lyn and G(alpha) (i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1. J Cell Sci 113(Pt 2): 349-357.
33. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BA (1998) Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339(7): 424-428.
34. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA (2013) PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinumresistant ovarian cancer. J Clin Oncol 31(35): 4400-4406.
35. O'Shannessy DJ, Somers EB, Smale R, Fu YS (2013) Expression of folate receptor-alpha (FRA) in gynecologic malignancies and its relationship to the tumor type. Int J Gynecol Pathol 32(3): 258-268.
36. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338(2): 284-293.
37. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH (2001) Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195(4): 451-456.
38. Prentice LM, Klausen C, Kalloger S, Kobel M, McKinney S, Santos JL, Kenney C, Mehl E, Gilks CB, Leung P, Swenerton K, Huntsman DG, Aparicio SA (2007) Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med 5: 33.
39. Ross JF, Chaudhuri PK, Ratnam M (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73(9): 2432-2443.
40. Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG (2009) Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360(26): 2719-2729.
41. Sieh W, Kobel M, Longacre TA, Bowtell DD, Defazio A, Goodman MT, Hogdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjaer SK, Jensen A, Hogdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, Garcia-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ (2013) Hormonereceptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14(9): 853-862.
42. Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, Kjaer SK (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 16(6): 1160-1166.
43. Song H, Ramus SJ, Quaye L, DiCioccio RA, Tyrer J, Lomas E, Shadforth D, Hogdall E, Hogdall C, McGuire V, Whittemore AS, Easton DF, Ponder BA, Kjaer SK, Pharoah PD, Gayther SA (2006) Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis 27(11): 2235-2242.
44. Spannuth WA, Sood AK, Coleman RL (2010) Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 10(3): 431-437.
45. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353): 609-615.
46. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, Sarantopoulos A, de Jong JS, Arts HJ, van der Zee AG, Bart J, Low PS, Ntziachristos V (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 17(10): 1315-1319.
47. Veggian R, Fasolato S, Menard S, Minucci D, Pizzetti P, Regazzoni M, Tagliabue E, Colnaghi MI (1989) Immunohistochemical reactivity of a monoclonal antibody prepared against human ovarian carcinoma on normal and pathological female genital tissues. Tumori 75(5): 510-513.
48. Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD (2013) Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol Oncol 131(2): 493-498.
49. Williams E, Martin S, Moss R, Durrant L, Deen S (2012) Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival. Virchows Arch 461(1): 33-39.
50. Wu M, Gunning W, Ratnam M (1999) Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 8(9): 775-782.